CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 110 enrolled
Drug / intervention
1% chloroprocaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03324984
NCT03324984Phase 2Completed

Comparison of 1% Chloroprocaine vs. Hyperbaric Bupivacaine Spinals in Patients Undergoing Hemorrhoidectomies in an Ambulatory Surgery Center: A Double-Blind Randomized Controlled Pilot Trial.

Montefiore Medical Center·interventional·Posted Oct 30, 2017·Updated Feb 28, 2025

In Brief

A Phase 2 clinical trial evaluating 1% chloroprocaine and 0.75% bupivacaine for Return of Motor and Sensory Blockade and 2 related conditions. Completed, enrolled 110 participants across 1 site.

Detailed Summary

The use of 1% Chloroprocaine (PF) spinal anesthesia will reduce the recovery times and discharge time of patients undergoing hemorrhoidectomies as compared to 0.75% bupivacaine spinal. The primary objective is to compare the recovery times (return of motor and sensory function) and discharge time (voiding time) between 2-Chloroprocaine and 0.75% bupivacaine spinal anesthesia for hemorrhoidectomies. This is a randomized, prospective study assigning patients to either 2-Chloroprocaine (PF) or 0.75% bupivacaine spinal anesthesia group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 30, 2017
Enrollment StartSep 11, 2019
Primary CompletionFeb 1, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 8.7 years ago

Interventions

1% chloroprocainedrug

In 2018, 1% Chloroprocaine was approved by the FDA for spinal anesthesia use.

0.75% bupivacainedrug

Bupivacaine is used on label